comprehensive -WSS

comprehensive

author：fashion 2025-09-30 20:17:55 - browse：5

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Covid vaccines: Private market messier than government rollout

explore

WSS

Pharma patents targeted by Biden in move to slash drug prices

How the Dana

CMS should re

How the Dana

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Wikipedia

comprehensive

focus

Apple is now the first public company to be valued at $3 trillion

Pharma patents targeted by Biden in move to slash drug prices

What does generative AI mean for health care? We asked experts

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

After affirmative action ruling, medical educators look to 'holistic review'

Pharma patents targeted by Biden in move to slash drug prices

Walensky prepares to leave CDC — and Congress — behind

How one patient went off dialysis — and others can too

Trump demands the U.S. pay no more for drugs than other countries … again

How the Dana

knowledge

Pharma patents targeted by Biden in move to slash drug prices

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Medicaid, Medicare dual

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Americans' trust in science, scientist continues decline: Report

knowledge

hotspot

explore

knowledge